【导读】肝细胞癌（HCC）中肿瘤内免疫浸润在与肿瘤细胞的相互作用中起着关键作用。然而，其表型和相关空间结构尚未明确。11月7日，中国医学科学院与北京协和医院研究人员合作共同在期刊《Cell Death&Disease》上发表了题为“DKK1+ ...

【导读】ME2在癌症发生过程中经常升高，可能是癌症治疗的靶点，它催化苹果酸转化为丙酮酸。然而，控制ME2活性的过程目前仍不清楚。11月11日，贵州医科大学罗鹏教授研究团队在期刊《Cell Death&Disease》上发表了研究论文，题为“PRMT1 ...

Despite medical advancements, the late-stage diagnosis of HCC remains a major challenge, which underscores the need for more ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Despite medical advancements, the late-stage diagnosis of HCC remains a major challenge, which underscores the need for more effective early detection strategies. Circulating tumor cells (CTCs ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...